| Leukemia, Myelocytic, Acute
Daurismo vs Xospata
Side-by-side clinical, coverage, and cost comparison for leukemia, myelocytic, acute.Deep comparison between: Daurismo vs Xospata with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXospata has a higher rate of injection site reactions vs Daurismo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xospata but not Daurismo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Daurismo
Xospata
At A Glance
Oral
Daily
Hedgehog pathway inhibitor
Oral
Daily
FLT3 inhibitor
Indications
- Leukemia, Myelocytic, Acute
- Leukemia, Myelocytic, Acute
Dosing
Leukemia, Myelocytic, Acute 100 mg orally once daily on days 1-28 in combination with cytarabine 20 mg subcutaneously twice daily on days 1-10 of each 28-day cycle; treat for a minimum of 6 cycles in the absence of unacceptable toxicity or loss of disease control.
Leukemia, Myelocytic, Acute 120 mg orally once daily with or without food; in the absence of disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for a clinical response.
Contraindications
—
- Hypersensitivity to gilteritinib or any of the excipients
Adverse Reactions
Most common (>=10%) Anemia, hemorrhage, febrile neutropenia, thrombocytopenia, fatigue, edema, mucositis, pyrexia, chest pain, musculoskeletal pain, muscle spasm, nausea, constipation, abdominal pain, diarrhea, vomiting, dyspnea, cough, decreased appetite, dysgeusia, dizziness, headache, rash, pneumonia, hyponatremia, platelet count decreased, weight decreased, white blood cell count decreased, atrial arrhythmia, renal insufficiency
Serious (>=5%) Febrile neutropenia, pneumonia, hemorrhage, anemia, sepsis
Most common (>=10%) transaminase increased, myalgia/arthralgia, fatigue/malaise, fever, mucositis, edema, rash, noninfectious diarrhea, dyspnea, nausea, cough, constipation, eye disorders, headache, dizziness, hypotension, vomiting, renal impairment, abdominal pain, neuropathy, insomnia, dysgeusia
Serious differentiation syndrome, posterior reversible encephalopathy syndrome, prolonged QT interval, pancreatitis
Pharmacology
Glasdegib is a Hedgehog pathway inhibitor that binds to and inhibits Smoothened, a transmembrane protein involved in hedgehog signal transduction, and exhibits concentration-dependent QTc prolongation.
Gilteritinib is a small molecule inhibitor of multiple receptor tyrosine kinases, including FLT3; it inhibits FLT3 receptor signaling and proliferation in cells expressing FLT3-ITD and FLT3 tyrosine kinase domain mutations, and induces apoptosis in leukemic cells expressing FLT3-ITD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Daurismo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (4/12) · Qty limit (11/12)
Xospata
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (3/12) · Qty limit (12/12)
UnitedHealthcare
Daurismo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Xospata
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Daurismo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Xospata
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DaurismoView full Daurismo profile
XospataView full Xospata profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.